论文信息 - RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma - 字舞流文

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

R. Greil | M. Winderlich | Kibum Kim | I. Fleury | G. Hess | J. Trotman | G. Nowakowski | A. Peters | D. Yoon | R. Marks | P. Mondello | E. Joffe | A. Sporchia | L. Sabatelli | M. Ku | N. Kurukulasuriya | G. Salles | P. Zinzani | R. Córdoba | Eva E. Waltl